Engineered immune cells take aim at Hard-to-Treat lupus
Disease control
Not yet recruiting
This early-stage study tests a new treatment called C-CAR168 for people with lupus nephritis (kidney inflammation from lupus) that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy harmful cells driving the di…
Phase: PHASE1, PHASE2 • Sponsor: AbelZeta Inc. • Aim: Disease control
Last updated May 17, 2026 03:13 UTC